The Tyrosine Kinase Receptor EphA2 in Alveolar Macrophages Provides a Protective Role in Host Defense Against Pneumocystis Pneumonia
The Journal of Infectious Diseases · 03.08.2026 · 234 (1) · 154-163
DOI: 10.1093/infdis/jiag228 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 23.04.2026. Verfasst von Theodore J Kottom und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Thoracic Diseases Research Unit, Mayo Clinic College of Medicine, 221 First Street SW, Rochester,…. Hauptthemen laut MEDLINE: Macrophages, Alveolar, Pneumonia, Pneumocystis, Receptor, EphA2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Mayo Foundation, Walter and Leonore Annenberg Foundation, NIH.
Abstract (Originalsprache)
Background
Alveolar macrophages (AMs) are central to host defense against Pneumocystis, mediating organism clearance while also contributing to lung inflammation. EphA2, a transmembrane receptor that binds fungal β-glucans, has emerged as a regulator of host–pathogen interactions, but its role in AM responses during Pneumocystis pneumonia (PCP) is unknown.
Methods
We evaluated AM inflammatory responses to Pneumocystis β-glucans in the presence and absence of EphA2. In vivo studies used a CD4-depleted mouse model of PCP comparing wild-type and EphA2-deficient (EphA2−/−) mice. Lung cytokine responses and organism burden were assessed. Additionally, EphA2 signaling was pharmacologically inhibited using ALW-II-41-27 during trimethoprim-sulfamethoxazole treatment.
Results
EphA2 deficiency significantly reduced AM proinflammatory cytokine responses to Pneumocystis β-glucans. In CD4-depleted PCP mice, EphA2−/− animals demonstrated decreased lung inflammatory cytokines, but increased organism burden compared to controls. Pharmacologic inhibition of EphA2 during antimicrobial therapy significantly suppressed lung inflammation.
Conclusions
EphA2 signaling plays a critical role in AM-mediated host defense against Pneumocystis by promoting inflammatory responses necessary for organism control. However, this pathway also contributes to lung inflammation. Targeting EphA2 may represent a novel strategy to modulate inflammation during severe PCP while preserving antimicrobial defense.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Thoracic Diseases Research Unit, Mayo Clinic College of Medicine, 221 First Street SW, Rochester, Minnesota 55905, USA.
ORCID-Profile: Theodore J Kottom, Conrad C Achilonu, Kimberly E Stelzig, Andrew H Limper
Förderung
- Mayo Foundation
- Walter and Leonore Annenberg Foundation
- NIH
- NHLBI NIH HHS
Zitieren
APA
Kottom, T. J., Pellegrino, M., Achilonu, C. C., Stelzig, K. E., & Limper, A. H. (2026). The Tyrosine Kinase Receptor EphA2 in Alveolar Macrophages Provides a Protective Role in Host Defense Against Pneumocystis Pneumonia. The Journal of Infectious Diseases, 234(1), 154-163. https://doi.org/10.1093/infdis/jiag228
Vancouver
Kottom TJ, Pellegrino M, Achilonu CC, Stelzig KE, Limper AH. The Tyrosine Kinase Receptor EphA2 in Alveolar Macrophages Provides a Protective Role in Host Defense Against Pneumocystis Pneumonia. The Journal of Infectious Diseases. 2026;234(1):154-163. doi:10.1093/infdis/jiag228
BibTeX
@article{Kottom2026,
author = {Kottom, Theodore J and Pellegrino, Madeline and Achilonu, Conrad C and Stelzig, Kimberly E and Limper, Andrew H},
title = {The Tyrosine Kinase Receptor EphA2 in Alveolar Macrophages Provides a Protective Role in Host Defense Against Pneumocystis Pneumonia},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {234},
number = {1},
pages = {154--163},
doi = {10.1093/infdis/jiag228}
}
EUVIMED